Coya Therapeutics (COYA) announced that dosing of ALS patients in the company’s ALSTARS trial of COYA 302 has commenced.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA:
- Coya Therapeutics: Strong Financial Position and Upcoming Catalysts Support Buy Rating
- Coya Therapeutics Reports Q3 2025 Financial Results
- Coya Therapeutics reports Q3 EPS (13c), consensus (30c)
- Coya Therapeutics price target raised to $17 from $16 at Lake Street
- Coya Therapeutics announces results from COYA 303 in vivo animal study